Print page content Print
Increase text size Decrease text size
Text Size


Equine Rhinopneumonitis Vaccine Killed Virus


PNEUMABORT-K® + 1b is the only equine vaccine labeled for use in pregnant mares to aid in the prevention of abortion due to equine herpesvirus type 1 (EHV-1) infections, as well as to help prevent respiratory infections caused by EHV-1p and EHV-1b.

In the fifth, seventh and ninth months of gestation mares need a vaccine labeled to help protect against abortion caused by EHV-1. In fact, pregnant mares have a more than four times greater risk of abortion due to EHV-1 when not vaccinated.1-4

Collapse All
    • The 1b subgroup of EHV-1 continues to be an important group, as are abortions associated with EHV-1 infections.5
    • PNEUMABORT-K + 1b is uniquely adjuvanted for improved immune responses.
    • Recommended for whole-herd management — including geldings, stallions and mares — where there is evidence of EHV-1 in the herd population.
    • For pregnant mares, aseptically administer one 2-mL dose intramuscularly during the fifth, seventh and ninth months of each pregnancy.
    • For young horses to aid in the prevention of EHV-1 respiratory infections, aseptically administer one 2-mL dose intramuscularly after weaning, followed by a second 2-mL dose three to four weeks later. Revaccinate with a single 2-mL dose six months after the second primary dose and annually thereafter.
    • To ensure proper placement and retention of the vaccine, inject deep into the heavy muscles of the hindquarter.
    • Mild exercise to promote absorption is recommended for one week after injection.
    • Maiden and barren mares that come in contact with vaccinated pregnant mares should be vaccinated on the same schedule as the pregnant mares with which they are in contact. Mares more than five months pregnant at the time of arrival on a farm should be vaccinated upon arrival and at two-month intervals until foaling.
    • Pregnant mares that are in contact with mares that have aborted EHV-1 infected fetuses should be vaccinated. Such vaccination may provide immunity for those mares in the group which are not incubating an abortigenic infection at the time of vaccination.

    Always read and follow label indications.

    Store in the dark at 2° to 7°C (35° to 45°F). AVOID FREEZING. SHAKE VIGOROUSLY to assure uniform suspension of the vaccine. When used according to instructions, local or systemic reactions rarely occur. An occasional local swelling or induration at the site of injection may be encountered. Do not vaccinate within 60 days before slaughter. Use entire contents when first opened. In case of anaphylactoid reaction administer epinephrine.

  • 1 Bryans JT, Allen GP. Application of a chemically inactivated, adjuvanted vaccine to control abortigenic infection of mares by equine herpesvirus 1. Dev Biol Stand. 1982;52:493-498.

    2 Tengelsen LA, Yamini B, Mullaney TP, et al. A 12-year retrospective study of equine abortion in Michigan. J Vet Diagn Invest. 1997;9(3):303-306.

    3 Giles RC, Donahue JM, Hong CB, et al. Causes of abortion, stillbirth, and perinatal death in horses: 3,527 cases. 1986-1991. J Am Vet Med Assoc. 1993;203(8):1170-1175.

    4 Hong CB, Donahue JM, Giles RC, et al. Equine abortion and stillbirth in central Kentucky during 1988 and 1989 foaling seasons. J Vet Diagn Invest. 1993;5(4):560-566.

    5 Paillot R, Case R, Ross J, Newton R, Nugent J. Equine Herpes Virus-1: Virus, Immunity and Vaccines, The Open Veterinary Science Journal 2008;2:68-91.




Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.